EP3283466A1 - Ksr antagonists - Google Patents
Ksr antagonistsInfo
- Publication number
- EP3283466A1 EP3283466A1 EP16780908.6A EP16780908A EP3283466A1 EP 3283466 A1 EP3283466 A1 EP 3283466A1 EP 16780908 A EP16780908 A EP 16780908A EP 3283466 A1 EP3283466 A1 EP 3283466A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- compound
- pharmaceutically acceptable
- acceptable salt
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 title abstract description 8
- 102100021001 Kinase suppressor of Ras 1 Human genes 0.000 claims abstract description 90
- 238000000034 method Methods 0.000 claims abstract description 52
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 42
- 201000011510 cancer Diseases 0.000 claims abstract description 35
- 239000003112 inhibitor Substances 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 328
- 150000001875 compounds Chemical class 0.000 claims description 327
- 150000003839 salts Chemical class 0.000 claims description 174
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 102
- 125000000217 alkyl group Chemical group 0.000 claims description 101
- 229940124647 MEK inhibitor Drugs 0.000 claims description 96
- 125000004432 carbon atom Chemical group C* 0.000 claims description 87
- 229910052760 oxygen Inorganic materials 0.000 claims description 75
- 229910052717 sulfur Inorganic materials 0.000 claims description 75
- 210000004027 cell Anatomy 0.000 claims description 69
- 125000002837 carbocyclic group Chemical group 0.000 claims description 64
- 229910052757 nitrogen Inorganic materials 0.000 claims description 64
- 125000001188 haloalkyl group Chemical group 0.000 claims description 35
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 34
- 125000002947 alkylene group Chemical group 0.000 claims description 33
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical group CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 31
- 229960004066 trametinib Drugs 0.000 claims description 31
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 30
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 30
- 229940124597 therapeutic agent Drugs 0.000 claims description 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 25
- -1 RDEAl 19 Chemical compound 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 claims description 12
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 12
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 11
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 11
- PEKZLFZZBGBOPJ-UHFFFAOYSA-N COC=1C=C2C(=NC=NC2=CC=1OC)NC1=C(C=C(C=C1)OC1=CC=CC=C1)C Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)NC1=C(C=C(C=C1)OC1=CC=CC=C1)C PEKZLFZZBGBOPJ-UHFFFAOYSA-N 0.000 claims description 11
- 101001137642 Homo sapiens Kinase suppressor of Ras 1 Proteins 0.000 claims description 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- AAIKMGJGHJBDRC-UHFFFAOYSA-N 6,7-dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3C)c2cc1OC AAIKMGJGHJBDRC-UHFFFAOYSA-N 0.000 claims description 9
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 claims description 9
- LIXKSHWZJNNZHG-UHFFFAOYSA-N 6,7-dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine hydrochloride Chemical compound Cl.COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3C)c2cc1OC LIXKSHWZJNNZHG-UHFFFAOYSA-N 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 7
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 7
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 7
- 230000002489 hematologic effect Effects 0.000 claims description 7
- MWUFVYLAWAXDHQ-HMNLTAHHSA-N (2e,5s,6s,8z,10r,11s)-17-(ethylamino)-5,6,15-trihydroxy-10,11-dimethyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,8,14,16-pentaene-7,13-dione Chemical compound O([C@@H](C)[C@H](C)\C=C/C(=O)[C@@H](O)[C@@H](O)C/C=C/1)C(=O)C=2C\1=CC(NCC)=CC=2O MWUFVYLAWAXDHQ-HMNLTAHHSA-N 0.000 claims description 6
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 claims description 6
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 claims description 6
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 claims description 6
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 claims description 6
- QSENMPAGYMUVDE-UHFFFAOYSA-N 4-[3-chloro-4-(1-methylimidazol-2-yl)sulfanylanilino]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1NC(C=C1Cl)=CC=C1SC1=NC=CN1C QSENMPAGYMUVDE-UHFFFAOYSA-N 0.000 claims description 6
- XXSSGBYXSKOLAM-UHFFFAOYSA-N 5-bromo-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide Chemical compound OCC(O)CONC(=O)C1=CC(Br)=C(F)C(F)=C1NC1=CC=C(I)C=C1F XXSSGBYXSKOLAM-UHFFFAOYSA-N 0.000 claims description 6
- LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 claims description 6
- ZEZHPEIEEFTILY-QMMMGPOBSA-N G-573 Chemical compound C[C@H](O)CONC(=O)C=1OC2=C(F)C=NC=C2C=1NC1=CC=C(I)C=C1F ZEZHPEIEEFTILY-QMMMGPOBSA-N 0.000 claims description 6
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims description 6
- 229950003054 binimetinib Drugs 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 229950002592 pimasertib Drugs 0.000 claims description 6
- 229950008933 refametinib Drugs 0.000 claims description 6
- 229950010746 selumetinib Drugs 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229960002271 cobimetinib Drugs 0.000 claims description 5
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims description 3
- FMETVQKSDIOGPX-UHFFFAOYSA-N RK-24466 Chemical compound C1=2C(N)=NC=NC=2N(C2CCCC2)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 FMETVQKSDIOGPX-UHFFFAOYSA-N 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 208000026807 lung carcinoid tumor Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 35
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
- 108010003046 KSR-1 protein kinase Proteins 0.000 abstract description 79
- 125000005843 halogen group Chemical group 0.000 description 110
- 101001137640 Homo sapiens Kinase suppressor of Ras 2 Proteins 0.000 description 94
- 101000749824 Homo sapiens Connector enhancer of kinase suppressor of ras 2 Proteins 0.000 description 91
- 102100021000 Kinase suppressor of Ras 2 Human genes 0.000 description 91
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 66
- 229940126086 compound 21 Drugs 0.000 description 65
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 59
- 201000010099 disease Diseases 0.000 description 54
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 52
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 52
- 239000007787 solid Substances 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 description 25
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 description 25
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 230000003993 interaction Effects 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 125000000623 heterocyclic group Chemical group 0.000 description 14
- 102000016914 ras Proteins Human genes 0.000 description 14
- 238000002372 labelling Methods 0.000 description 13
- 230000026731 phosphorylation Effects 0.000 description 13
- 238000006366 phosphorylation reaction Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 108010014186 ras Proteins Proteins 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 238000003828 vacuum filtration Methods 0.000 description 12
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 11
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000011664 signaling Effects 0.000 description 11
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 102000043136 MAP kinase family Human genes 0.000 description 10
- 108091054455 MAP kinase family Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 230000032683 aging Effects 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 101710113436 GTPase KRas Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000007605 air drying Methods 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229960004592 isopropanol Drugs 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 229960002685 biotin Drugs 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- LLLHRNQLGUOJHP-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 LLLHRNQLGUOJHP-UHFFFAOYSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 208000009329 Graft vs Host Disease Diseases 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 208000012902 Nervous system disease Diseases 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 206010052779 Transplant rejections Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000006471 dimerization reaction Methods 0.000 description 6
- 208000024908 graft versus host disease Diseases 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 6
- LFTHSVHVSCMOQP-UHFFFAOYSA-N 6-methoxy-7-(3-morpholin-4-ylpropoxy)-4-(4-phenoxyanilino)quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1NC(C=C1)=CC=C1OC1=CC=CC=C1 LFTHSVHVSCMOQP-UHFFFAOYSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical group C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 208000020446 Cardiac disease Diseases 0.000 description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 3
- 208000006029 Cardiomegaly Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 3
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 101150063416 add gene Proteins 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000006800 cellular catabolic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 102000047208 human KSR2 Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 229960004891 lapatinib Drugs 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- PRXJISLGJWHPJR-UHFFFAOYSA-N 2,3-dimethyl-1-nitro-4-phenoxybenzene Chemical compound CC1=C(C=CC(=C1C)OC1=CC=CC=C1)[N+](=O)[O-] PRXJISLGJWHPJR-UHFFFAOYSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- COHVZTXZLIRSTM-UHFFFAOYSA-N 2-methyl-1-nitro-4-phenoxybenzene Chemical compound C1=C([N+]([O-])=O)C(C)=CC(OC=2C=CC=CC=2)=C1 COHVZTXZLIRSTM-UHFFFAOYSA-N 0.000 description 2
- LOXZCYZBCSAIIF-UHFFFAOYSA-N 2-methyl-4-phenoxyaniline Chemical compound C1=C(N)C(C)=CC(OC=2C=CC=CC=2)=C1 LOXZCYZBCSAIIF-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- QGNGOGOOPUYKMC-UHFFFAOYSA-N 4-hydroxy-6-methylaniline Chemical compound CC1=CC(O)=CC=C1N QGNGOGOOPUYKMC-UHFFFAOYSA-N 0.000 description 2
- WOYZXEVUWXQVNV-UHFFFAOYSA-N 4-phenoxyaniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC=C1 WOYZXEVUWXQVNV-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 239000012820 MEK1 Inhibitor Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- WIMXXYSUEFRDHM-UHFFFAOYSA-N N-(2,3-dimethyl-4-phenoxyphenyl)-6,7-dimethoxyquinazolin-4-amine Chemical compound COc1cc2ncnc(Nc3ccc(Oc4ccccc4)c(C)c3C)c2cc1OC WIMXXYSUEFRDHM-UHFFFAOYSA-N 0.000 description 2
- CFUOOOACDNLMAN-UHFFFAOYSA-N N-(2,3-dimethyl-4-phenoxyphenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride Chemical compound Cl.COc1cc2ncnc(Nc3ccc(Oc4ccccc4)c(C)c3C)c2cc1OC CFUOOOACDNLMAN-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- ZCILODAAHLISPY-UHFFFAOYSA-N biphenyl ether Natural products C1=C(CC=C)C(O)=CC(OC=2C(=CC(CC=C)=CC=2)O)=C1 ZCILODAAHLISPY-UHFFFAOYSA-N 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 2
- 229960002465 dabrafenib Drugs 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000001102 germinal center b cell Anatomy 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- DAEZHJNJHQAEPE-UHFFFAOYSA-N 2,3-dimethyl-4-nitrophenol Chemical compound CC1=C(C)C([N+]([O-])=O)=CC=C1O DAEZHJNJHQAEPE-UHFFFAOYSA-N 0.000 description 1
- JIAFRSCJRLEEMW-UHFFFAOYSA-N 2,3-dimethyl-4-phenoxyaniline Chemical compound CC1=C(N)C=CC(=C1C)OC1=CC=CC=C1 JIAFRSCJRLEEMW-UHFFFAOYSA-N 0.000 description 1
- RVZMPNMUBCAPQO-UHFFFAOYSA-N 2,4-dimethoxyquinazoline Chemical compound C1=CC=CC2=NC(OC)=NC(OC)=C21 RVZMPNMUBCAPQO-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KYOBKVLSIPEVFU-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]-3-methylphenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1C KYOBKVLSIPEVFU-UHFFFAOYSA-N 0.000 description 1
- WDXQBNWJVOGCQW-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]-3-methylphenol;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1C WDXQBNWJVOGCQW-UHFFFAOYSA-N 0.000 description 1
- HNJNNCPPISFBGR-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1 HNJNNCPPISFBGR-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- XPYQFIISZQCINN-QVXDJYSKSA-N 4-amino-1-[(2r,3e,4s,5r)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrate Chemical compound O.O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 XPYQFIISZQCINN-QVXDJYSKSA-N 0.000 description 1
- WRVHQEYBCDPZEU-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinoline Chemical compound C1=CC(Cl)=C2C=C(OC)C(OC)=CC2=N1 WRVHQEYBCDPZEU-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- BGHJKXFDTLEYEO-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-N-(4-phenoxyphenyl)quinazolin-4-imine Chemical compound CN1C=NC(=NC2=CC=C(C=C2)OC3=CC=CC=C3)C4=CC(=C(C=C41)OC)OC BGHJKXFDTLEYEO-UHFFFAOYSA-N 0.000 description 1
- QUTVVSIKCNRGEB-UHFFFAOYSA-N 6,7-dimethoxy-n-(4-phenoxyphenyl)quinolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1NC(C=C1)=CC=C1OC1=CC=CC=C1 QUTVVSIKCNRGEB-UHFFFAOYSA-N 0.000 description 1
- JDNGAWOVVWZRSS-UHFFFAOYSA-N 6,7-dimethoxy-n-(4-phenoxyphenyl)quinolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=CC=1NC(C=C1)=CC=C1OC1=CC=CC=C1 JDNGAWOVVWZRSS-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical compound O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- BGHJKXFDTLEYEO-BZZOAKBMSA-N COC=1C=C2/C(/N=CN(C2=CC=1OC)C)=N/C1=CC=C(C=C1)OC1=CC=CC=C1 Chemical compound COC=1C=C2/C(/N=CN(C2=CC=1OC)C)=N/C1=CC=C(C=C1)OC1=CC=CC=C1 BGHJKXFDTLEYEO-BZZOAKBMSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 125000006605 Cn-m alkenyl group Chemical group 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- ZCGOMHNNNFPNMX-YHYDXASRSA-N Levocabastinum Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)C2CCC(CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-YHYDXASRSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 230000005723 MEK inhibition Effects 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N-3,4-tridhydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 125000000815 N-oxide group Chemical group 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- XDZITNILNWAQFC-UHFFFAOYSA-N N1=CN=CC2=CC=CC=C12.C1(=CC=CC=C1)C1=CC=CC=C1 Chemical class N1=CN=CC2=CC=CC=C12.C1(=CC=CC=C1)C1=CC=CC=C1 XDZITNILNWAQFC-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DMWVGXGXHPOEPT-UHFFFAOYSA-N Src Inhibitor-1 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC(C=C1)=CC=C1OC1=CC=CC=C1 DMWVGXGXHPOEPT-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- MSLJYSGFUMYUDX-UHFFFAOYSA-N Trimidox Chemical compound ON=C(N)C1=CC(O)=C(O)C(O)=C1 MSLJYSGFUMYUDX-UHFFFAOYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- XMYKNCNAZKMVQN-NYYWCZLTSA-N [(e)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 description 1
- RRDRHWJDBOGQHN-JWCTVYNTSA-N [2-[(2s,5r,8s,11s,14r,17s,22s)-17-[(1r)-1-hydroxyethyl]-22-[[(2s)-2-[[(2s,3r)-3-hydroxy-2-[[(2s)-2-[6-methyloctanoyl(sulfomethyl)amino]-4-(sulfomethylamino)butanoyl]amino]butyl]amino]-4-(sulfomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15 Chemical compound CCC(C)CCCCC(=O)N(CS(O)(=O)=O)[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O RRDRHWJDBOGQHN-JWCTVYNTSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 1
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960002559 chlorotrianisene Drugs 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 229940108538 colistimethate Drugs 0.000 description 1
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 238000012926 crystallographic analysis Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical class CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- RDYMFSUJUZBWLH-UHFFFAOYSA-N endosulfan Chemical compound C12COS(=O)OCC2C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl RDYMFSUJUZBWLH-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 1
- 229960005073 erlotinib hydrochloride Drugs 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960002899 hydroxyprogesterone Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- RVGLGHVJXCETIO-UHFFFAOYSA-N lodoxamide Chemical compound OC(=O)C(=O)NC1=CC(C#N)=CC(NC(=O)C(O)=O)=C1Cl RVGLGHVJXCETIO-UHFFFAOYSA-N 0.000 description 1
- 229960004305 lodoxamide Drugs 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229940125374 mitogen-activated extracellular signal-regulated kinase inhibitor Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- GYLCBOOGXYLHKE-UHFFFAOYSA-N n,n-bis(4-methoxyphenyl)hydroxylamine Chemical compound C1=CC(OC)=CC=C1N(O)C1=CC=C(OC)C=C1 GYLCBOOGXYLHKE-UHFFFAOYSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229950006410 tezacitabine Drugs 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 229960005526 triapine Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940086984 trisenox Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Definitions
- This invention relates to antagonists of Kinase Suppressor of Ras (KSR) and more particularly to KSR inhibitors that are useful for the treatment of cancer.
- Ras-mutant cancers unlike RAF -mutant cancers, it has thus far not been possible to inhibit the MAPK pathway sufficiently using therapeutically safe doses of RAF and MEK inhibitors partly due to the limited therapeutic window offered by these drug targets.
- One in four of all human cancers contain mutant forms of Ras and Ras is the one of the most frequently mutated oncogenes (see e.g., Pylayeva-Gupta, et al., Nat. Rev. Cancer, 2011, 11 (11), 761-774).
- K-Ras and N-Ras substitutions are frequently observed in pancreatic (95% K-Ras), colon (47% K-Ras), lung (35% K-Ras) and melanoma (28% N-Ras).
- Y 1 is N or CH
- W and X are each independently selected from the group consisting of H, halo, and C1-4 alkyl;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group or a 3-6 membered heterocyclic group;
- Cy 1 is selected from the group consisting of:
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci -4 haloalkyl;
- R 3 is selected from the group consisting of H and halo
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 6 is absent or selected from the group consisting of H and Ci-4 alkyl
- At least one of W, X, R B , R 1 , R 2 , R 4 , R 5 , and R 6 is not H.
- the compound is a compound of Formula la:
- Y 1 is N.
- A is selected from the group consisting of N, NH,
- A is NH.
- L is O.
- W is selected from the group consisting of H, F, CI, Br, and CH 3 .
- X is selected from the group consisting of H, F, CI, Br, and CH 3 . In some embodiments, X is F.
- each R B is H. In some embodiments, two R B groups come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group. In some embodiments, two R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3-6 carbocyclic group selected from:
- two R groups come together, in combination with the carbon atoms to which they are attached, to form a phenyl group.
- two R B groups come together, in combination with the carbon atoms to which they are attached, to form a 3-6 membered heterocyclic group.
- two R B groups come together, in combination with the carbon atoms to which they are attached, to form a 3-6 membered heterocyclic group selected from:
- R is selected from the group consisting of H, F, OH, and CF 3 .
- R 2 is selected from the group consisting of H, F and CI.
- R 3 is H or CI. In some embodiments, R 3 is H.
- R 4 is selected from the group consisting of H and F.
- R 5 is selected from the group consisting of H, F, OH, and CF 3 .
- R 6 is absent. In some embodiments, R 6 is H or CH 3 . In some embodiments:
- Y 1 is ;
- W and X are each independently selected from the group consisting of H, halo, and CH 3 ;
- each R B is H;
- two R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3-6 carbocyclic group or a 3-6 membered heterocyclic group;
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci -4 haloalkyl;
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 6 is absent or CH 3 .
- Y 1 is ;
- A is selected from the group consisting of N, NH, N(CH 3 ), S, O, and CFb;
- L is selected from the group consisting of O, NH, S, and CEh;
- W is selected from the group consisting of H, CI, Br, and CH3;
- X is selected from the group consisting of H, F, CI, Br, and CH3;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and C1-4 haloalkyl;
- R 3 is H
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 6 is absent or CH 3 .
- Y 1 is N
- A is H
- W is selected from the group consisting of H, CI, Br, and CH 3 ;
- X is selected from the group consisting of H, F, CI, Br, and CH 3 ;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3 -6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and C1-4 haloalkyl;
- R 3 is H
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 6 is absent.
- the compound is a compound of Formula lb:
- the compound is a compound of Formula Ic:
- B is a C 3 -6 carbocyclic group or a 3-6 membered heterocyclic group.
- the compound is a compound of Formula Id:
- the compound is selected from the group consisting of:
- the compound is 6,7-dimethoxy-N-(2-methyl-4- phenoxyphenyl)quinazolin-4-amine, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 6,7-dimethoxy-N-(2-methyl-4- phenoxyphenyl)quinazolin-4-amine 2,2,2-trifluoroacetate. In some embodiments, the compound is 6,7-dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine hydrochloride.
- Y 1 is N or CH
- W and X are each independently selected from the group consisting of H, halo, and Ci -4 alkyl;
- Cy 1 is selected from the group consisting of:
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and C1-4 haloalkyl; R 3 is selected from the group consisting of H and halo; and
- R 2 and R 4 are each independently selected from the group consisting of H and halo; or
- R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group or a 3-6 membered heterocyclic group;
- R 6 is absent or selected from the group consisting of H and C alkyl.
- the compound is a compound of Formula Ila:
- Y 1 is N.
- A is NH.
- L is O.
- W is selected from the group consisting of H, CI, Br, and CH .
- X is selected from the group consisting of H, F, CI, Br, and CH 3 . In some embodiments, X is F.
- R 1 is selected from the group consisting of H, F, OH, and CF3.
- R 2 is selected from the group consisting of H and F.
- R 3 is selected from the group consisting of H and CI. In some embodiments, R 3 is H.
- R 4 is selected from the group consisting of H and F.
- R 5 is selected from the group consisting of H, F, OH,
- R 4 and R 5 are each H. In some embodiments, R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group. In some embodiments, R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group selected from:
- R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a phenyl group. In some embodiments, R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form 3-6 membered heterocyclic group. In some embodiments, R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form 3-6 membered heterocyclic group selected from:
- R 6 is absent. In some embodiments, R 6 is selected from the group consisting of H and CH 3 .
- A is selected from the group consisting of N, NH, N(CH 3 ), S, O, and CH2;
- L is selected from the group consisting of O, NH, S, and CH 2 ;
- W and X are each independently selected from the group consisting of H, halo, and CH 3 ;
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci -4 haloalkyl;
- R 3 is selected from the group consisting of H and CI;
- R 2 and R 4 are each independently selected from the group consisting of H and halo; or
- R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C 3-6 carbocyclic group or a 3-6 membered heterocyclic group;
- R 6 is absent or CH 3 .
- Y 1 is N
- A is selected from the group consisting of N, NH, N(CH 3 ), S, O, and CH2;
- L is selected from the group consisting of O, NH, S, and CH2;
- W is selected from the group consisting of H, CI, Br, and CH 3 ;
- X is selected from the group consisting of H, F, CI, Br, and CH 3 ;
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and C1-4 haloalkyl;
- R 3 is selected from the group consisting of H and CI;
- R 2 and R 4 are each independently selected from the group consisting of H and halo; or alternatively, R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group or a 3-6 membered heterocyclic group; and
- R 6 is absent or CH 3 .
- Y 1 is N
- A is NH
- W is selected from the group consisting of H, CI, Br, and CH3;
- X is selected from the group consisting of H, F, CI, Br, and CH3;
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and C1-4 haloalkyl;
- R 3 is selected from the group consisting of H and CI;
- R 2 and R 4 are each independently selected from the group consisting of H and halo; or
- R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C 3 -6 carbocyclic group or a 3-6 membered heterocylic group;
- R 6 is absent.
- Y 1 is N
- A is NH
- W is selected from the group consisting of H, CI, Br, and CH3;
- X is selected from the group consisting of H, F, CI, Br, and CH 3 ;
- R 1 is selected from the group consisting of H, halo, OH, C1-4 alkyl, and C1-4 haloalkyl;
- R 2 is selected from the group consisting of H and halo
- R 3 is selected from the group consisting of H and CI;
- R 4 and R 5 are each H;
- R 6 is absent.
- the compound is a compound of Formula lib:
- the compound is a compound of Formula lie:
- B is a C 3 - 6 carbocyclic group or a 3-6 membered heterocyclic group.
- the compound is a compound of Formula lid:
- the compound is selected from the rou consisting of:
- L is selected from the group consisting of O, H, S, and Ci-3 alkylene
- W and X are each independently selected from the group consisting of H, halo, and Ci -4 alkyl;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3 -6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci -4 haloalkyl;
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 3 is selected from the group consisting of H and halo
- R 6 is selected from the group consisting of H, C 1-3 alkyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl.
- L is selected from the group consisting of O, NH, S, and CH2. In some embodiments, L is 0.
- W is selected from the group consisting of H, CI, Br, and CH 3 .
- X is selected from the group consisting of H, F, CI, Br, and CH3. In some embodiments, X is F.
- each R B is H. In some embodiments, two R B groups come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group. In some embodiments, two R B groups come together, in combination with the carbon atoms to which they are attached, to form a phenyl group.
- R 1 is selected from the group consisting of H, F, OH, and CF 3 .
- R 2 is selected from the group consisting of H and F.
- R 3 is selected from the group consisting of H and CI. In some embodiments, R 3 is H.
- R 4 is selected from the group consisting of H and F.
- R 5 is selected from the group consisting of H, F, OH, and CF 3 .
- R 6 is selected from the group consisting of H, Ci -3 alkyl, and Cs- 6 cycloalkyl and 5-6 membered heterocycloalkyl. In some embodiments, R 6 is selected from the group consisting of H, CH 3 , cyclopentyl, 3-piperidinyl, 4- piperidinyl, and 3-pyrrolidinyl.
- L is selected from the group consisting of O, NH, S, and CH 2 ;
- W and X are each independently selected from the group consisting of H, halo, and CH 3 ;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3- 6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci -4 haloalkyl;
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 3 is selected from the group consisting of H and CI.
- R 6 is selected from the group consisting of H, Ci -3 alkyl, C 3- 6 cycloalkyl and 3- 6 membered heterocycloalkyl.
- L is selected from the group consisting of O, NH, S, and CH_;
- W is selected from the group consisting of H, CI, Br, and CH 3 ;
- X is selected from the group consisting of H, F, CI, Br, and CH 3 ; each R B is H; or
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3-6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci- 4 haloalkyl;
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 3 is selected from the group consisting of H and CI.
- R 6 is selected from the group consisting of H, Ci -3 alkyl, C 5-6 cycloalkyl, and 5-6 membered heterocycloalkyl.
- W is selected from the group consisting of H, CI, Br, and CH 3 ;
- X is selected from the group consisting of H, F, CI, Br, and CH 3 ;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3-6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci-4 haloalkyl;
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 3 is selected from the group consisting of H and CI.
- R 6 is selected from the group consisting of H, CH 3 , C5-6 membered cycloalkyl, and 5-6 membered heterocycloalkyl.
- the compound is a compound of Formula Ilia:
- the compound is a compound of Formula Illb:
- B is a C3-6 carbocyclic g a 3-6 membered heterocycloalkyl group.
- the compound is a compound of Formula IIIc:
- the compound is selected from the group consisting of:
- the compound is 7-cyclopentyl-5-(4-phenoxyphenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof.
- the present application further provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound provided herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
- the present application further provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound provided herein.
- the present application further provides a method of treating cancer in a patient in need thereof, comprising:
- the cancer is selected from the group consisting of breast cancer, prostate cancer, esophageal cancer, colon cancer, endometrial cancer, brain cancer, bladder cancer, skin cancer, cancer of the uterus, cancer of the ovary, lung cancer, pancreatic cancer, renal cancer, prostate cancer, gastric cancer, stomach cancer, and hematological cancer.
- the lung cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, and lung carcinoid tumor.
- the non-small cell lung cancer comprises an adenocarcinoma of the lung or squamous cell cancer of the lung.
- the hematological cancer is selected from the group consisting of leukemia, lymphoma, and multiple myeloma.
- the leukemia is selected from the group consisting of acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), chronic myeloid leukemia (CML), hairy cell leukemia, T-cell prolymphocytic leukemia, juvenile myelomonocytic leukemia, and follicular lymphoma.
- ALL acute lymphoblastic leukemia
- CLL chronic lymphocytic leukemia
- AML acute myelogenous leukemia
- CML chronic myeloid leukemia
- hairy cell leukemia T-cell prolymphocytic leukemia
- juvenile myelomonocytic leukemia juvenile myelomonocytic leukemia
- follicular lymphoma follicular lymphoma
- the lymphoma is Hodgkin's lymphoma or non- Hodgkin's lymphoma.
- the method further comprises administering an additional therapeutic agent.
- the additional therapeutic agent is a chemotherapeutic agent.
- the additional therapeutic agent is a KSR inhibitor or a MEK inhibitor.
- the additional therapeutic agent is a MEK inhibitor.
- the MEK inhibitor is selected from the group consisting of trametinib, selumetinib, binimetinib, refametinib, pimasertib, cobimetinib, AZD8330, R04987655, R05126766, WX-554, E6201, MSC1936369B, PD-325901, CI-1040, RDEA119, CH5126766, GDC-0623, G-573, TAK-733, TAK- 133, CI-1 040/PD1 84352, AZD6244, PD318088, PD98059, PD334581, RDEAl 19, 6-methoxy-7-(3-morpholin-4-yl-propoxy)-4-(4-phenoxy-phenylamino)quinoline-3- carbonitrile, and 4-[3-Chloro-4-(l -methyl- lH-imidazol-2-ylsulfanyl)phenyla
- the present application further provides a method of inhibiting a KSR in a cell, comprising contacting the cell with an effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof.
- the present application further provides a method of inhibiting a KSR and a MEK in a cell, comprising contacting the cell with an effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof.
- FIG. 3 shows labeling of ATP-binding pockets of purified KSR2:MEK1 complexes using an activity based probe (ATPbiotin).
- FIG. 4 shows a graphical representation for ATPbiotin probe labeling of KSR2-MEK1 complexes in the presence of increasing free ATP as shown in FIG. 3. Corresponding ICso values are listed for both KSR2 and MEK1.
- FIG. 5 shows results of a screen for direct competitors of ATP-biotin probe labeling of MEK and KSR.
- FIG. 6 shows a crystal structure of KSR2:MEK1, assembled via a face-to-face interaction. Within this arrangement, two key phospho-regulatory residues in MEK1, Ser218 and Ser222, are buried and protected from the action of RAF. Inset includes a magnified view of interactions between KSR2, MEKl , and Compound 21.
- Compounyd 21 and an extended segment that reinforces negative-regulatory interactions of KSR2 on MEKl are shown within 2
- FIGs. 7A-7G shows results of a biolayer inferometry assay.
- B-RAF and B- RAF mutants (F667E +/- R509H) were immobilized on sensor-heads and
- KSR2:MEK1 or MEKl assembly was monitored. Curves indicate dose ranges of KSR2:MEK1 or MEKl from 625 nM to 10 ⁇ . In all plots, association occurred from 0 to 660 seconds, and dissociation was monitored thereafter up to 1500 seconds. Compound 21 and trametinib were added in the presence of KSR2:MEK1 at a concentration of 25 ⁇ each.
- FIG. 8 shows phosphorylation of MEKl and KSR2:MEK1 with increasing amounts of B-RAF kinase over time. Reactions were initiated by the addition of 100 ⁇ ATP and halted at the indicated times. Each reaction was then immunoblotted and probed for pMEK and tMEK to detect RAF-mediated MEK phosphorylation.
- FIGs. 9A-9C show phosphorylation of MEK1, KSR2:MEK1, and
- KSR2 A690F :MEK1 by B-RAF over time in the presence of Compound 21 Relative pMEK was determined by quantification of band intensities from western blots using Image Lab Software 4.1.
- FIGs. 10A-10B show KSR1 knockdown and Compound 21 treatment similarly block FBS-induced ERK activation.
- HEK293 cells were serum starved for 24 hours and simultaneously treated with two independent siRNAs against KSR1.
- siNTC was used as a scrambled control. After induction with 5% FBS, cells were harvested at 0, 30, 60, and 120 seconds.
- FIG. 10B HEK293 cells were similarly serum starved and pre-treated with Compound 21 for 2 h before induction. The cells were then induced with FBS as in FIG. 10A.
- FIG. 11 shows a western blot analysis of the treatment of cells with the Compound 21 in combination with a MEK inhibitor, trametinib.
- the arrow indicates effective pathway knockdown by combination inhibitors.
- FIG. 12 shows Compound 21 enhancing the efficacy of the clinical MEK inhibitor trametinib within cancer cell lines containing K-Ras mutations.
- High BLISS scores indicate statistically significant synergy between Compound 21 and trametinib specifically within K-Ras mutant cells. Numbers listed within synergy matrices, representing % growth inhibition relative to DMSO controls, are mean of two replicates. Insets highlight dose responses of trametinib in the absence or presence of 1 ⁇ Compound 21.
- FIGs. 13A-13D show data validating that Compound 21 is synergistic with trametinib in Ras-mutant cells.
- FIG. 13A shows a BLISS score analysis of HCT-116, A549, A375, and SK-MEL-239 cells treated with Compound 21, sarcatinib, or lapatinib (range: 100-3000 in three-fold dilutions) in combination with trametinib (range: 0.01-100 in three-fold dilution).
- BLISS scores were calculated based on combination assays as shown in Figure 4A.
- FIG. 13B shows absolute BLISS score of the indicated drugs in combination with trametinib in Ras-mutant relative to RAF- mutant cell lines demonstrates selective synergy in Ras-mutant cell lines for
- FIGs. 13C-13D show log of the combination index (CI) graphs of Compound 21 in combination with trametinib in HCT-116 vs. SK-MEL-239 cells as compared to the fractional effect (Fa). Negative CI over a broad Fa range within HCT-116, but not SK-MEL-239, indicates strong synergy.
- FIGs. 14A-14B shows the increased potency of trametinib in the presence of Compound 21 within HCT-116 cells relative to the control cell line A375, which occurs through enhanced down-regulation of Ras-MAPK signaling (as measured by
- FIGs. 15A-15C show the results of in vitro cell assays using Compound 21 and HTC-116 cells (FIG. 15A), A549 cells (FIG. 15B), and LOVO cells (FIG. 15C).
- Combination drugs are increasingly recognized as a therapeutic modality for a variety of complex diseases including cancer (see, e.g., Glickman et al., Cell, 2012, 148(6), 1089-1098).
- drug combinations may be required to improve treatment responses, minimize adverse events, or minimize development of resistance.
- combination approaches have primarily focused on three strategies including co-targeting of a single pathway (see e.g., Chapman et al., Cancer Cell, 2014, 26(5), 603-604), different pathways (see e.g., Vora et al., Cancer Cell, 2014, 26(1), 136-149), or compensatory pathways (see e.g., Carver et al., Cancer Cell, 2011, 19(5), 575-586).
- KSR Ras driven tumors
- KSR controls Ras-dependent proliferation via direct interactions with several kinases in the MAPK cascade and also metabolism via AMP-activated protein kinase signaling (see e.g., Costanzo-Garvey et al., Cell Metab. 2009, 10(5), 366-378; Roy et al, Genes Dev. 2002, 16(4), 427-438; and Ritt et al., Methods Enzymol. 2006, 407, 224-237).
- KSR belongs to a family of highly related kinases, including KSRl and KSR2, and the human RAF kinases (A-RAF, B-RAF, C-RAF). KSRl and KSR2 share 61% overall amino acid identity, and 71% amino acid identity between kinase domains. While both KSRl and KSR2 can interact with RAF, MEK, and ERK, KSRl has been shown to be prominently involved in MAPK signaling, while KSR2 was shown to impact cell growth through its interaction and functional impact on AMPK (see e.g., Fernandez et al., Mol. Cell. Biol. 2012, 32(18), 3718-3731).
- KSRl knockout mice exhibit a rough hair phenotype
- KSR2 knockout mice display a severe obese phenotype
- Knockout of KSRl in RAS-driven tumor mouse models completely blocks tumorigenesis.
- KSRl appears to be essential for RAS-driven tumorigenesis but not required for normal homeostasis (see e.g., Blasco et al., Cancer Cell, 2011, 19(5), 652-653).
- KSR as a catalytically compromised kinase
- pseudokinase a catalytically compromised kinase
- Current models suggest that KSR functions as a scaffold to potentiate Ras signaling through the formation of macromolecular signaling complexes that include the Ras effector kinases RAF and MEK.
- KSR likely forms a high affinity complex with inactive forms of MEK but once engaged by active RasGTP-RAF complexes, KSR adopts a distinct state where it can instead drive MEK
- KSR antagonists Small molecules that could antagonize KSR dependent activities would be valuable tools that could be used to functionally annotate the pharmacology of this class of protein in Ras or RAF dependent cancers. Accordingly, the present application provides compounds that are useful as KSR antagonists and methods of using same. The following abbreviations may be used herein: calc. (calculated); d
- Y 1 is N or CH
- W and X are each independently selected from the group consisting of H, halo, and C1-4 alkyl; each R B is H; or
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3 -6 carbocyclic group or a 3-6 membered heterocyclic group;
- Cy 1 is selected from the group consisting of:
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci-4 haloalkyl;
- R 3 is selected from the group consisting of H and halo
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 6 is absent or selected from the group consisting of H and Ci-4 alkyl.
- At least one of W, X, R B , R 1 , R 2 , R 4 , R 5 , and R 6 is not H.
- Cy 1 is selected from the group consisting of:
- the compound of Formula I is a compound of Formula
- Y 1 is N. In some embodiments, Y 1 is CH.
- A is selected from the group consisting of N, NH, N(CH 3 ), S, O, and CH 2 .
- A is NH.
- A is N(CH 3 ).
- A is S.
- L is selected from the group consisting of O, NH, S, and CH 2 . In some embodiments, L is O. In some
- L is NH. In some embodiments, L is S. In some embodiments, L is CH2. In some embodiments, L is CH(OH). In some embodiments, L is CH(NH 2 ). In some embodiments, L is selected from the group consisting of CH(OH), CH(NH 2 ), CH(NHCH3), CH(NHCH 2 CH 3 ), CH(NHCH 2 CH 2 CH 3 ), CH(NHCH(CH 3 ) 2 ),
- W is selected from the group consisting of H, halo, and CH 3 . In some embodiments, W is selected from the group consisting of H, F, CI, Br, and Ci-4 alkyl. In some embodiments, W is selected from the group consisting of H, F, CI, Br, and CH 3 . In some embodiments, W is selected from the group consisting of H, CI, Br, and CH 3 . In some embodiments, W is H. In some embodiments, W is halo. In some embodiments, W is CI or Br. In some embodiments, W is C1-4 alkyl. In some embodiments, W is CH 3 .
- X is selected from the group consisting of H, halo, and
- X is selected from the group consisting of H, F, CI, Br, and Ci-4 alkyl. In some embodiments, X is selected from the group consisting of H, F, CI, Br, and CH 3 . In some embodiments, X is H. In some embodiments, X is halo. In some embodiments, X is selected from the group consisting of F, CI, and Br. In some embodiments, X is F. In some embodiments, X is Ci-4 alkyl. In some embodiments, X is CH 3 .
- each B is H.
- two R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3-6 carbocyclic group.
- two R B groups come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group selected from:
- two R B groups come together, in combination with the carbon atoms to which they are attached, to form a phenyl group.
- two R B groups come together, in combination with the carbon atoms to which they are attached, to form a 3-6 membered heterocyclic group. In some embodiments, two R B groups come together, in combination with the carbon atoms to which they are attached, to form a 3-6 membered heterocyclic group selected from:
- R is selected from the group consisting of H, halo, OH, and Ci-4haloalkyl.
- R 1 is selected from the group consisting of H, halo, OH, and CF 3 .
- R 1 is selected from the group consisting of H, F, CI, Br, OH, and Ci-4haloalkyl.
- R 1 is selected from the group consisting of H, F, CI, Br, OH, and CF 3 .
- R 1 is selected from the group consisting of H, F, OH, and CF 3 .
- R 2 is selected from the group consisting of H, F, CI, and Br. In some embodiments, R 2 is selected from the group consisting of H, F, and CI. In some embodiments, R 2 is selected from the group consisting of H and F. In some embodiments, R 2 is H. In some embodiments, R 2 is F.
- R 3 is H. In some embodiments, R 3 is halo. In some embodiments, R 3 is selected from the group consisting of F, CI, and Br. In some embodiments, R 3 is CI. In some embodiments, R 3 is selected from the group consisting of H and CI.
- R 4 is selected from the group consisting of H, F, CI, and Br. In some embodiments, R 4 is selected from the group consisting of H and F. In some embodiments, R 4 is H. In some embodiments, R 4 is F.
- R 5 is selected from the group consisting of H, halo, OH, and Ci-4 haloalkyl. In some embodiments, R 5 is selected from the group consisting of H, halo, OH, and CF 3 . In some embodiments, R 5 is selected from the group consisting of H, F, CI, Br, OH, and Cwhaloalkyl. In some embodiments, R 5 is selected from the group consisting of H, F, CI, Br, OH, and CF 3 . In some embodiments,
- R 5 is selected from the group consisting of H, F, OH, and CF 3 . In some embodiments, R 5 is H. In some embodiments, R 5 is F. In some embodiments, R 5 is OH. In some embodiments, R 5 is CF 3 .
- R 6 is absent. In some embodiments, R 6 is selected from the group consisting of H and Ci-4 alkyl. In some embodiments, R 6 is selected from the group consisting of H and CH 3 . In some embodiments, R 6 is H. In some embodiments, R 6 is CH 3 .
- A is selected from the group consisting of N, NH, N(CH 3 ), S, O, and CBb;
- L is selected from the group consisting of O, NH, S, and CH 2 ;
- W and X are each independently selected from the group consisting of H, halo, and CH 3 ;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3-6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci-4 haloalkyl;
- R 3 is selected from the group consisting of H and CI;
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 6 is absent or CH 3 .
- Y 1 is N
- A is selected from the group consisting of N, NH, N(CH 3 ), S, O, and CH 2 ;
- L is selected from the group consisting of O, NH, S, and CEb;
- W is selected from the group consisting of H, CI, Br, and CH 3 ;
- X is selected from the group consisting of H, F, CI, Br, and CH 3 ;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3 - 6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci-4 haloalkyl;
- R 3 is selected from the group consisting of H and CI;
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 6 is absent or CH 3 .
- Y 1 is N
- A is NH
- W is selected from the group consisting of H, CI, Br, and CH 3 ;
- X is selected from the group consisting of H, F, CI, Br, and CH 3 ;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3 - 6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci-4 haloalkyl;
- R 3 is selected from the group consisting of H and CI; and R 2 and R 4 are each independently selected from the group consisting of H and halo; and
- R 6 is absent.
- the compound of Formula I is a compound of Formula la:
- Y 1 is or CH
- A is selected from the group consisting of N, NH, N(Ci- 4 alkyl), S, O, and Ci -3 alkylene;
- L is selected from the group consisting of O, NH, S, and Ci -3 alkylene;
- W and X are each independently selected from the group consisting of H, halo, and Ci-4 alkyl;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3-6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci-4 haloalkyl;
- R 3 is selected from the group consisting of H and halo
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 6 is absent or selected from the group consisting of H and Ci-4 alkyl.
- the compound of Formula I is a compound of Formula lb:
- the compound of Formula I is a compound of Formula
- B is a C3-6 carbocyclic group or a 3-6 membered heterocyclic group
- A, W, X, L, R 1 , R 2 , R 3 , R 4 , and R 5 are as defined above for compounds of Formula I.
- the compound of Formula I is a compound of Formula
- the compound of Formula I is a pharmaceutically acceptable salt.
- the compound of Formula I is a hydrochloride (i.e. HCl) salt.
- the compound of Formula I is a 2,2,2,- trifluoroacetic acid (i.e., TFA) salt.
- the compound is 6,7-dimethoxy-N-(2-methyl-4- phenoxyphenyl)quinazolin-4-amine (21), or a pharmaceutically acceptable salt thereof.
- the compound is 6,7-dimethoxy-N-(2-methyl-4- phenoxyphenyl)quinazolin-4-amine 2,2,2-trifluoroacetate (21 -TFA).
- the compound is 6,7-dimethoxy-N-(2-methyl-4- phenoxyphenyl)quinazolin-4-amine hydrochloride (21 ⁇ ).
- Y 1 is N or CH
- W and X are each independently selected from the group consisting of H, halo, and Ci-4 alkyl;
- Cy 1 is selected from the group consisting of:
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci-4 haloalkyl;
- R 3 is selected from the group consisting of H and halo
- R 2 and R 4 are each independently selected from the group consisting of H and halo; or
- R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group or a 3-6 membered heterocyclic group;
- R 6 is absent or selected from the group consisting of H and C1-4 alkyl.
- the compound of Formula II is a compound of Formula
- Y 1 is N. In some embodiments, Y 1 is CH.
- A is selected from the group consisting of N, NH, N(CH 3 ), S, O, and CH2.
- A is NH.
- A is N(CH 3 ).
- A is S.
- A is O. In some embodiments, A is CH2. In some embodiments, A is selected from the group consisting of CH(OH), CH(NH 2 ), CH(NHCH 3 ),
- CH(NHCH 2 CH 3 ), CH(NHCH 2 CH2CH 3 ), CH(NHCH(CH 3 ) 2 ), CH(NHCH 2 CH(CH 3 )2), CH(NHC(CH 3 ) 3 ), and CH(NHCH 2 CH CH 2 ).
- L is selected from the group consisting of O, NH, S, and CH 2 . In some embodiments, L is O. In some
- W is selected from the group consisting of H, halo, and CH 3 . In some embodiments, W is selected from the group consisting of H, F, CI, Br, and Ci-4 alkyl. In some embodiments, W is selected from the group consisting of H, F, CI, Br, and CH3. In some embodiments, W is selected from the group consisting of H, CI, Br, and CH3. In some embodiments, W is H. In some embodiments, W is halo. In some embodiments, W is CI or Br. In some embodiments, W is C1-4 alkyl. In some embodiments, W is CH3.
- X is selected from the group consisting of H, halo, and
- X is selected from the group consisting of H, F, CI, Br, and Ci-4 alkyl. In some embodiments, X is selected from the group consisting of H, F, CI, Br, and CH 3 . In some embodiments, X is H. In some embodiments, X is halo. In some embodiments, X is selected from the group consisting of F, CI, and Br. In some embodiments, X is F. In some embodiments, X is Ci-4 alkyl. In some embodiments, X is CH3.
- R 1 is selected from the group consisting of H, halo, OH, and Ci- 4 haloalkyl. In some embodiments, R 1 is selected from the group consisting of H, halo, OH, and CF3. In some embodiments, R 1 is selected from the group consisting of H, F, CI, Br, OH, and Ci-4 haloalkyl. In some embodiments, R 1 is selected from the group consisting of H, F, CI, Br, OH, and CF3. In some embodiments,
- R 1 is selected from the group consisting of H, F, OH, and CF 3 .
- R 2 is selected from the group consisting of H, F, CI, and Br. In some embodiments, R 2 is selected from the group consisting of H, F, and CI. In some embodiments, R 2 is selected from the group consisting of H and F. In some embodiments, R 2 is H. In some embodiments, R 2 is F.
- R 3 is H. In some embodiments, R 3 is halo. In some embodiments, R 3 is selected from the group consisting of F, CI, and Br. In some embodiments, R 3 is CI. In some embodiments, R 3 is selected from the group consisting of H and CI.
- R 4 is selected from the group consisting of H, F, CI, and Br. In some embodiments, R 4 is selected from the group consisting of H, F, and CI. In some embodiments, R 4 is selected from the group consisting of H and F. In some embodiments, R 4 is H. In some embodiments, R 4 is F.
- R 5 is selected from the group consisting of H, halo,
- R 5 is selected from the group consisting of H, halo, OH, and CF3. In some embodiments, R 5 is selected from the group consisting of H, F, CI, Br, OH, and Ci -4 haloalkyl. In some embodiments, R 5 is selected from the group consisting of H, F, CI, Br, OH, and CF3. In some embodiments,
- R 5 is selected from the group consisting of H, F, OH, and CF3. In some embodiments, R 5 is H. In some embodiments, R 5 is F. In some embodiments, R 5 is OH. In some embodiments, R 5 is CF3.
- R 4 and R 5 are each H. In some embodiments, R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group. In some embodiments, R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group selected from:
- R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a phenyl group.
- R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form 3-6 membered heterocyclic group. In some embodiments, R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form 5-6 membered heteroaryl group. In some embodiments, R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form 3-6 membered heterocycloalkyl group. In some embodiments, R 4 and R 5 come together, in combination with the carbon atoms to which they are ected from:
- R 6 is absent. In some embodiments, R 6 is selected from the group consisting of H and Ci-4 alkyl. In some embodiments, R 6 is selected from the group consisting of H and CH 3 . In some embodiments, R 6 is H. In some embodiments, R 6 is CH3.
- Y 1 is N
- A is selected from the group consisting of N, H, N(CH 3 ), S, O, and CH2;
- L is selected from the group consisting of O, NH, S, and CH2;
- W and X are each independently selected from the group consisting of H, halo, and CH3;
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and C1-4 haloalkyl;
- R 3 is selected from the group consisting of H and CI.
- R 2 and R 4 are each independently selected from the group consisting of H and halo; or
- R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group
- R 6 is absent or CH 3 .
- Y 1 is N
- A is selected from the group consisting of N, NH, N(CH 3 ), S, O, and CHb;
- L is selected from the group consisting of O, NH, S, and CH2;
- W is selected from the group consisting of H, CI, Br, and CH 3 ;
- X is selected from the group consisting of H, F, CI, Br, and CH 3 ;
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci-4 haloalkyl;
- R 3 is selected from the group consisting of H and CI.
- R 2 and R 4 are each independently selected from the group consisting of H and halo; or
- R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group
- R 6 is absent or CH3.
- A is H
- W is selected from the group consisting of H, CI, Br, and CH 3 ;
- X is selected from the group consisting of H, F, CI, Br, and CH 3 ;
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and C1-4 haloalkyl;
- R 3 is selected from the group consisting of H and CI.
- R 2 and R 4 are each independently selected from the group consisting of H and halo; or
- R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group
- R 6 is absent.
- Y 1 is N
- A is H
- W is selected from the group consisting of H, CI, Br, and CH3;
- X is selected from the group consisting of H, F, CI, Br, and CH3;
- R 1 is selected from the group consisting of H, halo, OH, Ci-4 alkyl, and C1-4 haloalkyl;
- R 2 is selected from the group consisting of H and halo
- R 3 is selected from the group consisting of H and CI; R 4 and R 5 are each H; and
- R 6 is absent.
- the compound of Formula II is a compound of Formula
- Y 1 is N or CH
- Y 2 is selected from the group consisting of N, NH, and N(Ci-4 alkyl);
- A is selected from the group consisting of N, NH, N(Ci-4 alkyl), S, O, and C 1-3 alkylene;
- L is selected from the group consisting of O, NH, S, and Ci -3 alkylene;
- W and X are each independently selected from the group consisting of H, halo, and Ci -4 alkyl;
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci -4 haloalkyl;
- R 3 is selected from the group consisting of H and halo
- R 2 and R 4 are each independently selected from the group consisting of H and halo; or
- R 4 and R 5 come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group.
- the compound of Formula II is a compound of Formula lib:
- the compound of Formula II is a compound of Formula lie:
- B is a C 3 - 6 carbocyclic group or a 3-6 membered heterocyclic group
- A, W, X, L, R 1 , R 2 , and R 3 are as defined above for compounds of Formula II.
- B is a C3-6 carbocyclic group.
- B is a 3-6 membered heterocyclic group.
- the compound of Formula II is a compound of Formula lid:
- the compound of Formula II is selected from the group consisting of:
- the compound of Formula II is a pharmaceutically acceptable salt.
- the compound of Formula II is a hydrochloride (i.e. HC1) salt.
- the compound of Formula II is a 2,2,2,- trifluoroacetic acid (i.e., TFA) salt.
- L is selected from the group consisting of O, NH, S, and Ci -3 alkylene;
- W and X are each independently selected from the group consisting of H, halo, and Ci-4 alkyl;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and C1-4 haloalkyl;
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 3 is selected from the group consisting of H and halo
- R 6 is selected from the group consisting of H, C1-3 all y 1, C 3 -6 cycloalkyl and 3- 6 membered heterocycloalkyl.
- L is selected from the group consisting of O, NH, S, and CH2. In some embodiments, L is O.
- W is selected from the group consisting of H, halo, and CH3. In some embodiments, W is selected from the group consisting of H, F, CI, Br, and Ci-4 alkyl. In some embodiments, W is selected from the group consisting of H, F, CI, Br, and CH3. In some embodiments, W is selected from the group consisting of H, CI, Br, and CH3. In some embodiments, W is H. In some embodiments, W is halo. In some embodiments, W is CI or Br. In some embodiments, W is C1-4 alkyl. In some embodiments, W is CH3.
- X is selected from the group consisting of H, halo, and CH3. In some embodiments, X is selected from the group consisting of H, F, CI, Br, and Ci-4 alkyl. In some embodiments, X is selected from the group consisting of H, F, CI, Br, and CH 3 . In some embodiments, X is H. In some embodiments, X is halo. In some embodiments, X is selected from the group consisting of F, CI, and Br. In some embodiments, X is F. In some embodiments, X is C1-4 alkyl. In some embodiments, X is CH 3 .
- each R B is H. In some embodiments, two R B groups come together, in combination with the carbon atoms to which they are attached, to form a C 3-6 carbocyclic group. In some embodiments, two R B groups come together, in combination with the carbon atoms to which they are attached, to form a phenyl group.
- R 1 is selected from the group consisting of H, halo,
- R 1 is selected from the group consisting of H, halo, OH, and CF 3 . In some embodiments, R 1 is selected from the group consisting of H, F, CI, Br, OH, and Ci- 4 haloalkyl. In some embodiments, R 1 is selected from the group consisting of H, F, CI, Br, OH, and CF 3 . In some embodiments,
- R 1 is selected from the group consisting of H, F, OH, and CF 3 .
- R 2 is selected from the group consisting of H, F, CI, and Br. In some embodiments, R 2 is selected from the group consisting of H and F. In some embodiments, R 2 is H. In some embodiments, R 2 is F.
- R 3 is H. In some embodiments, R 3 is halo. In some embodiments, R 3 is selected from the group consisting of F, CI, and Br. In some embodiments, R 3 is CI. In some embodiments, R 3 is selected from the group consisting of H and CI.
- R 4 is selected from the group consisting of H, F, CI, and Br. In some embodiments, R 4 is selected from the group consisting of H and F. In some embodiments, R 4 is H. In some embodiments, R 4 is F.
- R 5 is selected from the group consisting of H, halo, OH, and Ci -4 haloalkyl. In some embodiments, R 5 is selected from the group consisting of H, halo, OH, and CF3. In some embodiments, R 5 is selected from the group consisting of H, F, CI, Br, OH, and Ci -4 haloalkyl. In some embodiments, R 5 is selected from the group consisting of H, F, CI, Br, OH, and CF3. In some embodiments,
- R 5 is selected from the group consisting of H, F, OH, and CF3. In some embodiments, R 5 is H. In some embodiments, R 5 is F. In some embodiments, R 5 is OH. In some embodiments, R 5 is CF3.
- R 6 is selected from the group consisting of H, Ci-3 alkyl, and C3-6 cycloalkyl. In some embodiments, R 6 is selected from the group consisting of H, Ci-3 alkyl, and C5-6 cycloalkyl. In some embodiments, R 6 is selected from the group consisting of H, Ci -3 alkyl, and cyclopentyl. In some embodiments, R 6 is selected from the group consisting of H, CH3, and C 5-6 cycloalkyl. In some embodiments, R 6 is selected from the group consisting of H, CH 3 , and cyclopentyl.
- R 6 is selected from the group consisting of H, C1-3 alkyl, and C 5 -6 cycloalkyl and 5-6 membered heterocycloalkyl. In some embodiments, R 6 is selected from the group consisting of H, CH3, cyclopentyl, 3-piperidinyl, 4-piperidinyl, and 3- pyrrolidinyl.
- L is selected from the group consisting of O, NH, S, and CH2;
- W and X are each independently selected from the group consisting of H, halo, and CH 3 ;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci -4 haloalkyl;
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 3 is selected from the group consisting of H and CI.
- R 6 is selected from the group consisting of H, Ci-3 alkyl, and C3-6 cycloalkyl.
- L is selected from the group consisting of O, NH, S, and CBb;
- W is selected from the group consisting of H, CI, Br, and CH 3 ;
- X is selected from the group consisting of H, F, CI, Br, and CH3;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci-4 haloalkyl;
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 3 is selected from the group consisting of H and CI.
- R 6 is selected from the group consisting of H, C1-3 alkyl, and C5-6 cycloalkyl.
- W is selected from the group consisting of H, CI, Br, and CH 3 ;
- X is selected from the group consisting of H, F, CI, Br, and CH 3 ;
- each R B is H;
- R B groups come together, in combination with the carbon atoms to which they are attached, to form a C3-6 carbocyclic group
- R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, Ci-4 alkyl, and Ci- 4 haloalkyl;
- R 2 and R 4 are each independently selected from the group consisting of H and halo;
- R 3 is selected from the group consisting of H and CI.
- R 6 is selected from the group consisting of H, CH 3 , and C5-6 membered cycloalkyl.
- the compound of Formula III is a compound of Formula Ilia:
- the compound of Formula III is a compound of Formula Illb:
- B is a C 3-6 carbocyclic group or a 3-6 membered heterocyclic group
- W, X, R 1 , R 2 , R 3 , and R 6 are as defined above for compounds of Formula III.
- B is a C 3-6 carbocyclic group.
- B is a 3-6 membered heterocyclic group.
- the compound of Formula III is a compound of Formula IIIc:
- the compound of Formula III is a pharmaceutically acceptable salt.
- the compound of Formula III is a hydrochloride (i.e. HC1) salt.
- the compound of Formula III is a 2,2,2,-trifluoroacetic acid (i.e., TFA) salt.
- the compound of Formula III is selected from the group consisting of:
- the compound is 7-cyclopentyl-5-(4-phenoxyphenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-amine (94), or a pharmaceutically acceptable salt thereof.
- the present application further provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound provided herein (e.g., a compound of Formula I, a compound of Formula II, a compound of Formula III, or a compound selected from group the consisting of compounds (1)-(114)) or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
- the present invention also includes pharmaceutically acceptable salts of the compounds described herein.
- pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
- examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
- non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
- suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
- the compounds described herein include
- the compounds provided herein can be administered in the form of pharmaceutical compositions; thus, the methods described herein can include administering pharmaceutical compositions provided herein.
- the present application provides a pharmaceutical composition comprising a compound provided herein (e.g., a compound of Formula I, a compound of Formula II, a compound of Formula III or a compound selected from group the consisting of compounds (1)-(114)), or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.
- compositions can be prepared as described herein or elsewhere, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.
- Administration may be pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral, or parenteral.
- Parenteral administration may include, but is not limited to intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular injection or infusion; or intracranial, (e.g., intrathecal, intraocular, or intraventricular) administration.
- Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
- Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container.
- an excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
- compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
- excipients include, without limitation, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose,
- the formulations can additionally include, without limitation, lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; flavoring agents, or combinations thereof.
- lubricating agents such as talc, magnesium stearate, and mineral oil
- wetting agents such as talc, magnesium stearate, and mineral oil
- emulsifying and suspending agents such as methyl- and propylhydroxy-benzoates
- sweetening agents such as methyl- and propylhydroxy-benzoates
- the active compounds can be effective over a wide dosage range and are generally administered in a therapeutically effective amount. It will be understood, however, that the amount of the compound actually administered and the schedule of administration will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of
- the compounds provided herein, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
- the reactions for preparing compounds described herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis.
- suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, (e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature).
- a given reaction can be carried out in one solvent or a mixture of more than one solvent.
- suitable solvents for a particular reaction step can be selected by the skilled artisan.
- Preparation of compounds described herein can involve the protection and deprotection of various chemical groups.
- the need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art.
- the chemistry of protecting groups can be found, for example, in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., Wiley & Sons, Inc., New York (1999).
- Reactions can be monitored according to any suitable method known in the art.
- product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 3 ⁇ 4 or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin layer chromatography (TLC).
- HPLC high performance liquid chromatography
- LCMS liquid chromatography-mass spectroscopy
- TLC thin layer chromatography
- Compounds can be purified by those skilled in the art by a variety of methods, including high performance liquid chromatography (FfPLC) and normal phase silica chromatography.
- FfPLC high performance liquid chromatography
- FfPLC normal phase silica chromatography
- each divalent linking substituent include both the forward and backward forms of the linking substituent.
- - NR(CR'R")n- includes both -NR(CR'R") n - and -(CR'R") n NR-.
- the Markush variables listed for that group are understood to be linking groups.
- n-membered where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n.
- piperidinyl is an example of a 6-membered heterocycloalkyl ring
- pyrazolyl is an example of a 5-membered heteroaryl ring
- pyridyl is an example of a 6- membered heteroaryl ring
- 1,2,3,4-tetrahydro-naphthalene is an example of a 10- membered cycloalkyl group.
- the phrase "optionally substituted” means unsubstituted or substituted.
- substituted means that a hydrogen atom is removed and replaced by a substituent. It is to be understood that substitution at a given atom is limited by valency. For example, where one or more bonds are shown as optionally being a single or double bond ⁇ i.e., ) ; it is understood that the bonds comply with standard valency rules.
- Cn-m indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include Ci-4, Ci-6, and the like.
- C n -m alkyl employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched, having n to m carbons.
- alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, R-propyl, isopropyl, «-butyl, tert- butyl, isobutyl, sec-butyl; higher homologs such as 2 -methyl- 1 -butyl, n-pentyl, 3- pentyl, w-hexyl, 1,2,2-trimethylpropyl, and the like.
- the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms.
- C n -m alkenyl refers to an alkyl group having one or more double carbon-carbon bonds and having n to m carbons.
- Example alkenyl groups include, but are not limited to, ethenyl, «-propenyl, isopropenyl, rc-butenyl, sec- butenyl, and the like.
- the alkenyl moiety contains 2 to 4 carbon atoms.
- C n -m alkylene employed alone or in combination with other terms, refers to a divalent alkyl linking group having n to m carbons.
- alkylene groups include, but are not limited to, ethan-l,2-diyl, propan- 1,3-diyl, propan-l,2-diyl, butan-l,4-diyl, butan-l,3-diyl, butan-l,2-diyl, 2-methyl- propan-l,3-diyl, and the like.
- the alkylene moiety contains 2 to 6, 2 to 4, 2 to 3, 1 to 6, 1 to 4, or 1 to 2 carbon atoms.
- Carbocycle refers to an aromatic (e.g., phenyl) or non-aromatic cyclic hydrocarbon including cyclized alkyl and/or alkenyl groups.
- Carbocycles include, for example, 3-6 ring forming carbon atoms (i.e., C 3 -6
- carbocycle can be mono- or polycyclic (e.g., having two or more fused rings).
- the carbocycle is a C5-6 carbocycle.
- Example carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and phenyl.
- halo refers to F, CI, Br, or I. In some embodiments, a halo is F, CI, or Br. In some embodiments, a halo is F.
- Cn-mhaloalkyl refers to an alkyl group having from one halogen atom to 2s+l halogen atoms which may be the same or different, where "s" is the number of carbon atoms in the alkyl group, wherein the alkyl group has n to m carbon atoms.
- the haloalkyl group is fluorinated only.
- the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- heterocycle refers to a heteroaryl or heterocycloalkyl group having at least one heteroatom ring member selected from O, N, and S.
- the heterocycle is a 3-6 membered heterocycle.
- the heterocycle is a 5-6 membered heterocycle.
- the heterocycle is a heteroaryl.
- the heterocycle is a heterocycloalkyl.
- heteroaryl refers to an aromatic heterocycle having at least one heteroatom ring member selected from O, N, and S.
- the heteroaryl ring has 1, 2, 3, or 4 heteroatom ring members independently selected from O, N, and S.
- any ring-forming N in a heteroaryl moiety can be an N-oxide.
- the heteroaryl has 4-6 ring atoms and 1 , 2, 3 or 4 heteroatom ring members independently selected from O, N, and S.
- the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from O, N, and S.
- the heteroaryl is a five-membered or six-membered heteroaryl ring.
- exemplary heteroaryl groups include, but are not limited to, thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3- oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, 1,3,4-oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, triazinyl, and pyridazinyl.
- heterocycloalkyl refers to non-aromatic heterocycles having one or more ring-forming heteroatoms selected from O, N, and S.
- Example heterocycles include, but are not limited to, pyrrolidin-2-one, l,3-isoxazolidin-2-one, pyranyl, tetrahydropuran, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, benzazapene, and the like.
- the heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom.
- the heterocyclo alkyl is a 3-6 membered heterocycloalkyl having 1, 2, 3 or 4 heteroatom ring members independently selected from O, N, and S.
- the heterocycloalkyl is a 5-6 membered heterocycloalkyl.
- the term "compound" as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified.
- Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
- Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
- Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole.
- Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
- All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g. hydrates and solvates) or can be isolated.
- preparation of compounds can involve the addition of acids or bases to affect, for example, catalysis of a desired reaction or formation of salt forms such as acid addition salts.
- Example acids can be inorganic or organic acids and include, but are not limited to, strong and weak acids.
- Some example acids include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, ?-toluenesulfonic acid, 4- nitrobenzoic acid, methanesulfonic acid, benzenesulfonic acid, trifluoroacetic acid, and nitric acid.
- Some weak acids include, but are not limited to acetic acid, propionic acid, butanoic acid, benzoic acid, tartaric acid, pentanoic acid, hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, and decanoic acid.
- Example bases include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, and sodium bicarbonate.
- Some example strong bases include, but are not limited to, hydroxide, alkoxides, metal amides, metal hydrides, metal dialkylamides and arylamines, wherein; alkoxides include lithium, sodium and potassium salts of methyl, ethyl and t-butyl oxides; metal amides include sodium amide, potassium amide and lithium amide; metal hydrides include sodium hydride, potassium hydride and lithium hydride; and metal dialkylamides include lithium, sodium, and potassium salts of methyl, ethyl, n-propyl, wo-propyl, n-butyl, tert-butyl, trimethylsilyl and cyclohexyl substituted amides.
- the compounds provided herein, or salts thereof are substantially isolated.
- substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
- Partial separation can include, for example, a composition enriched in the compounds provided herein.
- Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds provided herein, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
- the present application further provides methods of treating a disease associated with KSR (e.g., upregulation of KSR expression) in a patient in need thereof.
- the disease associated with KSR is a disease mediated by KSR.
- the term "patient” refers to any animal, including mammals, for example, mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, primates, and humans.
- the patient is a human.
- the disease is selected from the group consisting of cancer, diabetes, obesity, a neurological disease, a skin disorder, an adverse effect associated with aging, a cardiovascular disease, organ transplant rejection, and graft versus host disease.
- the method comprises administering to a patient in need thereof a therapeutically effective amount of a compound provided herein (e.g., a compound of Formula I, a compound of Formula II, a compound of Formula III, or a compound selected from group the consisting of compounds (1)-(114)) or a pharmaceutically acceptable salt thereof.
- a compound provided herein e.g., a compound of Formula I, a compound of Formula II, a compound of Formula III, or a compound selected from group the consisting of compounds (1)-(114)
- the compound is a compound of Formula I, or a pharmaceutically acceptable salt thereof.
- the compound is a compound of Formula II, or a pharmaceutically acceptable salt thereof.
- the compound is a compound of Formula III, or a pharmaceutically acceptable salt thereof.
- the compound is selected from the group consisting of compounds (1)-(114), or a pharmaceutically acceptable salt thereof.
- the compound is 6,7- dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-
- the compound is 6,7- dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine 2,2,2-trifluoroacetate (21 -TFA). In some embodiments, the compound is 6,7-dimethoxy-N-(2-methyl-4- phenoxyphenyl)quinazolin-4-amine hydrochloride (21-HCI).
- the disease is cancer.
- the cancer is selected from the group consisting of breast cancer, prostate cancer, esophageal cancer, colon cancer, endometrial cancer, brain cancer, bladder cancer, skin cancer, cancer of the uterus, cancer of the ovary, lung cancer, pancreatic cancer, renal cancer, prostate cancer, gastric cancer, stomach cancer, and hematological cancer.
- the lung cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, and lung carcinoid tumor.
- the hematological cancer is selected from the group consisting of leukemia, lymphoma, and multiple myeloma.
- the hematological cancer is acute myeloblastic leukemia, chronic myeloid leukemia, B cell lymphoma, chronic lymphocytic leukemia (CLL), Non-Hodgkins lymphoma, hairy cell leukemia, Mantle cell lymphoma, Burkitt lymphoma, small lymphocytic lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, extranodal marginal zone lymphoma, activated B-cell like (ABC) diffuse large B cell lymphoma, or germinal center B cell (GCB) diffuse large B cell lymphoma.
- BCBC activated B-cell like
- GCB germinal center B cell
- the leukemia is selected from the group consisting of acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), chronic myeloid leukemia (CML), hairy cell leukemia, T-cell prolymphocytic leukemia, juvenile myelomonocytic leukemia, and follicular lymphoma.
- ALL acute lymphoblastic leukemia
- CLL chronic lymphocytic leukemia
- AML acute myelogenous leukemia
- CML chronic myeloid leukemia
- hairy cell leukemia T-cell prolymphocytic leukemia
- juvenile myelomonocytic leukemia juvenile myelomonocytic leukemia
- follicular lymphoma follicular lymphoma
- the lymphoma is Hodgkin's lymphoma or non- Hodgkin's lymphoma (NHL).
- the non-Hodgkin lymphoma is selected from relapsed NHL, refractory NHL, and recurrent follicular NHL.
- the disease is diabetes or obesity. In some embodiments, the disease is diabetes or obesity.
- the disease is a neurological disease (e.g., a mood disorder, age onset proteotoxic disease (i.e., Alzheimer's disease).
- the disease is a skin disorder (e.g., acne vulgaris).
- the disease is an adverse effect associated with aging (e.g., cellular degradation associated with aging).
- the disease is a cardiovascular disease (e.g., cardiac hypertrophy or cardiac disease).
- the disease is organ transplant rejection.
- the disease is graft versus host disease.
- the method further comprises administering an additional therapeutic agent to the patient.
- additional therapeutic agents include, but are not limited to antibiotic agents, antiviral agents, antifungal agents, anesthetics (e.g., for use in combination with a surgical procedure), anti-inflammatory agents, anti-allergic agents, and chemotherapeutic agents.
- the additional therapeutic agent comprises radiation therapy.
- a compound provided herein is administered in combination with an additional therapeutic agent during a surgical procedure.
- the additional therapeutic agent is administered simultaneously with a compound provided herein. In some embodiments, the additional therapeutic agent is administered after administration of a compound provided herein. In some embodiments, the additional therapeutic agent is administered prior to administration of a compound provided herein.
- the additional therapeutic agent is selected from the group consisting of an antibiotic agent, an antiviral agent, an antifungal agent, an anesthetic, or an anti-inflammatory agent (e.g., steroidal and non-steroidal antiinflammatories), and an anti-allergic agent.
- an antibiotic agent e.g., an antibiotic agent, an antiviral agent, an antifungal agent, an anesthetic, or an anti-inflammatory agent (e.g., steroidal and non-steroidal antiinflammatories), and an anti-allergic agent.
- Suitable medicaments include, but are not limited to, coriticosteroids such as dexamethasone or prednisone, aminoglycosides such as amikacin, gentamycin, tobramycin, streptomycin, netilmycin, and kanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridine; sulfonamides; polymyxin; chloramphenicol; neomycin; paramomycin; colistimethate; bacitracin; vancomycin; tetracyclines; rifampin and its derivatives ("rifampins”); cycloserine; beta-lactams; cephalosporins; amphotericins; fluconazole; flucytosine; natamycin; miconazole; keto
- ketorolac ketorolac
- suprofen cromolyn
- lodoxamide levocabastin
- naphazoline antazoline
- pheniramine or azalide antibiotic.
- the additional therapeutic agent is a chemotherapeutic agent.
- the additional therapeutic agent is a kinase inhibitor (e.g., KSR, MEK, Bcr-Abl, Flt-3, EGFR, HER2, JAK, c-MET, VEGFR, PDGFR, PI3K, cKit, IGF-1R, RAF, FAK, Akt mTOR, PIM, and AKT).
- the additional therapeutic agent can be a MEK inhibitor or a KSR inhibitor.
- the additional therapeutic agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, taxol, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methotrexate, temozolomide, cyclophosphamide, tipifarnib, gefitinib, erlotinib hydrochloride, antibodies to EGFR, imatinib mesylate, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine,
- a cytostatic agent cisplatin
- doxorubicin taxol
- etoposide etoposide
- irinotecan topotecan
- paclitaxel docetaxel
- the additional therapeutic agent is a MEK inhibitor.
- the MEK inhibitor is a MEK1 and MEK2 inhibitor.
- the MEK inhibitor is a MEK1 inhibitor.
- the MEK inhibitor is a MEK2 inhibitor.
- the MEK inhibitor is selected from the group consisting of trametinib, selumetinib, binimetinib, refametinib, pimasertib, cobimetinib, AZD8330, R04987655, R05126766, WX-554, E6201, MSC1936369B, PD-325901, CI-1040, RDEA1 19, CH5126766, GDC-0623, G-573, TAK-733, TAK-133, CI-1 040/PDl 84352, AZD6244, PD318088, PD98059, PD334581, RDEAl 19, 6-methoxy-7-(3-morpholin-4-yl-propoxy)-4-(4-phenoxy- phenylamino)quinoline-3-carbonitrile, and 4-[3-Chloro-4-(l-methyl-lH-imidazol-2- ylsulfanyl)phenylamin
- the present application further provides a method of treating a disease provided herein (e.g., cancer, diabetes, obesity, an adverse effect associated with aging, a neurological disease, a skin disorder, a cardiovascular disease, organ transplant rejection, and graft versus host disease) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound provided herein (e.g. , a compound of Formula I, a compound of Formula II, a compound of Formula III, or a compound selected from group the consisting of compounds (1)-(114)) or a pharmaceutically acceptable salt thereof, and an additional therapeutic agent provided herein.
- a compound provided herein e.g. , a compound of Formula I, a compound of Formula II, a compound of Formula III, or a compound selected from group the consisting of compounds (1)-(114)
- the compound is 6,7- dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine (21), or a
- the compound is 6,7- dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine 2,2,2-trifluoroacetate (21-TFA). In some embodiments, the compound is 6,7-dimethoxy-N-(2-methyl-4- phenoxyphenyl)quinazolin-4-amine hydrochloride (21-HC1). In some embodiments, the disease is cancer. In some embodiments, the disease is diabetes or obesity. In some embodiments, the disease is an adverse effect associated with aging (e.g., cellular degradation associated with aging). In some embodiments, the disease is a neurological disease (e.g., a mood disorder, age onset proteotoxic disease (i.e.,
- the disease is a skin disorder (e.g., acne vulgaris).
- the disease is a cardiovascular disease (e.g., cardiac hypertrophy or cardiac disease).
- the disease is organ transplant rejection.
- the disease is graft versus host disease.
- the additional therapeutic agent is a MEK inhibitor.
- the MEK inhibitor is a MEKl and MEK2 inhibitor.
- the MEK inhibitor is a MEKl inhibitor.
- the MEK inhibitor is a MEK2 inhibitor.
- the MEK inhibitor is selected from the group consisting of trametinib, selumetinib, binimetinib, refametinib, pimasertib, cobimetinib, AZD8330, R04987655, R05126766, WX-554, E6201, MSC1936369B, PD-325901, CI-1040, RDEA119, CH5126766, GDC-0623, G-573, TAK-733, TAK-133, CI-1 040/PD1 84352, AZD6244, PD318088, PD98059, PD334581, RDEA1 19, 6-methoxy-7-(3-morpholin-4-yl-propoxy)-4-(4-phenoxy- phenylamino)quinoline-3-carbonitrile, and 4- [3 -Chloro-4-( 1 -methyl- 1 H-imidazol-2- ylsulfanyl)pheny
- the present application further provides a method of treating a disease provided herein (e.g., cancer, diabetes, obesity, adverse effect associated with aging, a neurological disease, a skin disorder, a cardiovascular disease, organ transplant rejection, and graft versus host disease) in a patient in need thereof, comprising:
- a compound provided herein e.g., a compound of Formula I, a compound of Formula II, a compound of Formula III, or a compound selected from group the consisting of compounds (1)-(114)
- the compound is 6,7- dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine (21), or a
- the compound is 6,7- dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine 2,2,2-trifluoroacetate (21'TFA). In some embodiments, the compound is 6,7-dimethoxy-N-(2-methyl-4- phenoxyphenyl)quinazolin-4-amine hydrochloride (21-HCl).
- the disease associated with KSR is a disease mediated by KSR. In some embodiments, the disease is associated with KSRl and KSR2. In some embodiments, the disease is associated with KSRl or KSR2. In some embodiments, the disease is associated with KSRl. In some embodiments, the disease is associated with KSR2. In some embodiments, the disease is mediated by KSRl and KSR2. In some embodiments, the disease is mediated by KSRl or KSR2. In some embodiments, the disease is mediated by KSRl . In some embodiments, the disease is mediated by KSR2.
- the disease is cancer. In some embodiments, the disease is diabetes or obesity. In some embodiments, the disease is an adverse effect associated with aging (e.g., cellular degradation associated with aging). In some embodiments, the disease is a neurological disease (e.g., a mood disorder, age onset proteotoxic disease (i.e., Alzheimer's disease). In some embodiments, the disease is a skin disorder (e.g., acne vulgaris). In some embodiments, the disease is a
- cardiovascular disease e.g., cardiac hypertrophy or cardiac disease.
- the disease is organ transplant rejection.
- the disease is graft versus host disease.
- the KSR comprises KSRl . In some embodiments, the KSR comprises KSR2. In some embodiments, the KSR comprises KSRl and KSR2. In some embodiments, the KSR is KSRl . In some embodiments, the KSR is KSR2.
- the method further comprises administering an additional therapeutic agent provided herein.
- the additional therapeutic agent is a chemotherapeutic agent.
- the additional therapeutic agent is a MEK inhibitor.
- the MEK inhibitor is a MEK1 and MEK2 inhibitor.
- the MEK inhibitor is a MEK1 inhibitor.
- the MEK inhibitor is a MEK2 inhibitor.
- the MEK inhibitor is selected from the group consisting of trametinib, selumetinib, binimetinib, refametinib, pimasertib, cobimetmatib, AZD8330, R04987655, R05126766, WX-554, E6201, MSC1936369B, PD-325901, CI-1040, RDEA1 19, CH5126766, GDC-0623, G-573, TAK-733, TAK-133, CI-1 040/PDl 84352, AZD6244, PD318088, PD98059, PD334581, RDEA1 19, 6-methoxy-7-(3-morpholin-4-yl-propoxy)-4-(4-phenoxy- phenylamino)quinoline-3-carbonitrile, and 4-[3-Chloro-4-(l-methyl-lH-imidazol-2- ylsulfanyl)phenylamino
- the present application further provides a method of inhibiting KSR in a cell, comprising contacting the KSR with a compound provided herein (e.g. , a compound of Formula I, a compound of Formula II, a compound of Formula III, or a compound selected from group the consisting of compounds (1)-(114)) or a pharmaceutically acceptable salt thereof.
- a compound provided herein e.g. , a compound of Formula I, a compound of Formula II, a compound of Formula III, or a compound selected from group the consisting of compounds (1)-(114)
- the compound is 6,7-dimethoxy-N-(2- methyl-4-phenoxyphenyl)quinazolin-4-amine (21), or a pharmaceutically acceptable salt thereof.
- the compound is 6,7-dimethoxy-N-(2-methyl-4- phenoxyphenyl)quinazolin-4-amine 2,2,2-trifluoroacetate (21-TFA).
- the compound is 6,7-dimethoxy-N-(2-
- the KSR comprises KSR1. In some embodiments, the KSR comprises KSR2. In some embodiments, the KSR comprises KSR1 and KSR2. In some embodiments, the KSR is KSR1. In some embodiments, the KSR is KSR2.
- the present application further provides a method of inhibiting a KSR and a MEK in a cell, comprising contacting the cell with a compound provided herein (e.g., a compound of Formula I, a compound of Formula II, a compound of Formula III, or a compound selected from group the consisting of compounds (1)-(114)) or a pharmaceutically acceptable salt thereof.
- a compound provided herein e.g., a compound of Formula I, a compound of Formula II, a compound of Formula III, or a compound selected from group the consisting of compounds (1)-(114)
- the compound is 6,7- dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine (21), or a
- the compound is 6,7- dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine 2,2,2-trifluoroacetate (21-TFA). In some embodiments, the compound is 6,7-dimethoxy-N-(2-methyl-4- phenoxyphenyl)quinazolin-4-amine hydrochloride (21-HCl).
- the KSR comprises KSRl . In some embodiments, the KSR comprises KSR2. In some embodiments, the KSR comprises KSRl and KSR2. In some embodiments, the KSR is KSRl . In some embodiments, the KSR is KSR2.
- the MEK comprises MEKl. In some embodiments, the MEK comprises MEK2. In some embodiments, the MEK comprises MEKl and MEK2. In some embodiments, the MEK is MEKl . In some embodiments, the MEK is MEK2.
- the method further comprises contacting the cell with a MEK inhibitor.
- the MEK inhibitor is a MEKl and MEK2 inhibitor.
- the MEK inhibitor is a MEKl inhibitor.
- the MEK inhibitor is a MEK2 inhibitor.
- the MEK inhibitor is selected from the group consisting of trametinib, selumetinib, binimetinib, refametinib, pimasertib, cobimetinib, AZD8330, R04987655,
- phrases "pharmaceutically acceptable amount” or “therapeutically effective amount” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- a “pharmaceutically acceptable amount” or “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician.
- treating refers to one or more of (1) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology); and (2) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease or reducing or alleviating one or more symptoms of the disease.
- the pH of aqueous solutions was estimated using pH paper. Vacuum filtrations were carried out using a house vacuum line ( ⁇ 100 torr). In the individual procedures, the phrases “concentrated under vacuum” and “concentrated to dryness” mean that solvent was removed on a rotary evaporator using a diaphragm pump (with an automatic vacuum regulator) and then remaining traces of volatiles were removed on a high-vacuum ( ⁇ 1 torr) oil pump. Unless specified otherwise, the term “flask” refers to the round-bottomed variety.
- A375, HCT-116, and A549 cells were obtained from the American Type Culture Collection.
- SK-MEL-239 and 293H cells were rationally provided by the Poulikakos Lab at the Icahn School of Medicine at Mount Sinai.
- Cell lines were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum supplement with penicillin/streptomycin.
- Antibodies for detection of KSR1 (Product number: 4640), Flag-tag (Product number: 8146), GFP (Product number: 2555), pMEK (Product number: 9121), pERK (Product number: 9101), and MEK (Product number: 9122) were obtained from Cell Signaling. Western blotting was performed as described herein. For primary antibody detection, blots were washed several times and probed for 1 hr with anti-Mouse-HRP or anti-Rabbit-HRP (Cell Signaling) in 5% milk TBST.
- KSR1-FLAG (Addgene ID:25970) and MEKl-GFP (Addgene ID: 14746) plasmids were obtained from Addgene.
- the plasmids for expression of RAF was generated by DNA 2.0. Constructs harboring mutations were generated by site- directed mutagenesis (Agilent). DNA and siRNA transfections were carried out using Fugene 6 (Promega) and Dharmafect (GE Dharmacon) reagents in accordance with the manufacturer's recommendations.
- Trametinib and dabrafenib were obtained from Selleck Chemicals. All compounds were dissolved in DMSO and subsequently diluted for biochemical and cellular experiments.
- Example 1 The hydrochloride salt of Example 1 (i.e., compound 2-HCl) was suspended in a mixture of water and 95:5 CH 2 Cl 2 /MeOH, and then the pH of the aqueous phase was adjusted to 7-8 with a saturated solution of NaHC0 3 . The mixture was transferred to a separatory funnel, the layers were separated and the aqueous phase was extracted with a 95:5 mixture of CH2Cl 2 /MeOH (X2). The organic extracts were pooled, dried (Na 2 S04), filtered and concentrated to dryness: 3 ⁇ 4 NMR (400 MHz, DMSO-de) ⁇
- Table 1 shows Compounds 1-55, which were prepared according to one or more of the procedures provided herein, substituting the appropriate starting materials, and the corresponding characterization data. Table 1.
- the ATP-biotin assay was performed in buffer containing 25 mM Tris pH 7.5,
- hKSR2-rMEKl 150 mM NaCl, 10 mM MgCl 2 , and 2% DMSO.
- Purified hKSR2-rMEKl was assayed at 0.5 ⁇ .
- hKSR2-rMEKl was pre-incubated with 20 ⁇ of the indicated compounds for 15 minutes.
- ATP-biotin (Pierce Cat. #88310) was added to a final concentration of 2 ⁇ . Reactions were incubated at room temperature for 5 minutes before being stopped by the addition of 6X SDS loading dye. Samples were then electrophoresed on a 4-15% Tris-HCl SDS gradient gel, transferred to nitrocellulose membranes and blotted with Strepdavidin-HRP.
- Enhanced hKSR2-rMEKl 150 mM NaCl, 10 mM MgCl 2 , and 2% DMSO.
- chemiluminescence signals corresponding to labeling on KSR2 and MEKl were visualized and quantified using the Biodoc system (Biorad). Relative signals of Streptavidin HRP on bands corresponding to KSR2 and MEKl in the presence of compounds relative to DMSO controls were used to determine 'Percent Inhibition of ATP Probe Labeling'. Control experiments using ATP as a competitor were used to determine that the ATP-biotin probe specifically labels the active-site of KSR2 and MEKl. Representative results of the ATP-biotin assay are shown in FIGs. 1-2.
- ATP blotin transfers a desthio-biotin group via a reactive acyl-phosphate linkage onto active-site lysines when bound to either KSR2 or MEKl (Patricelli et al, Biochemistry, 2007, 46:350-358). It was confirmed that this label leads to a covalent attachment of desthiobiotin on KSR through detection with Streptavidin-HRP and intact mass spectrometry, the latter of which confirmed the addition of a two or one desthiobiotin groups (equivalent to a mass increase of 196.1 Da per desthiobiotin group) onto both KSR2 and MEKl, respectively, under non-saturating conditions.
- ATP bl0tm labeling competition screen samples were applied to a 4— 20% Tris-HCl gel, separated, and then transferred to a nitrocellulose membrane. The membrane was blocked with 5% bovine serum albumin diluted in TBS-T for 30 minutes and subsequently probed with the PierceTM High Sensitivity Streptavidin- F£RP. After several washes, the membranes were visualized using enhanced chemiluminescence on a Biodoc (Biorad). ICso values were determined under similar assay conditions with slight modifications: 0.1 ⁇ KSR2:MEK1 was pre-incubated with a dose-range of compounds (27 nM to 20 ⁇ in three-fold dilutions prior to the addition of ATP bl0tm . Assays were quenched and analysed similarly to as described above. Sigmoidal dose response curves were used to derive ICso values in Prism 6.0 (Graphpad). Assays were completed in triplicate.
- KSR2(KD) human KSR2 kinase domain
- MEKl(35-393) the final size exclusion chromatography step of the human KSR2 kinase domain (KSR2(KD)):MEKl(35-393) purification was performed in buffer containing 15 mM Bis-Tris pH 6.5, 150 NaCl, 1 mM TCEP, and 5 mM DTT.
- the KSR2(KD):MEKl(35-393) complex was concentrated to 10 mg/mL and incubated with 500 ⁇ Compound 21 » TFA. Aggregates were removed through centrifugation at 14,000 g for 10 minutes. Over a thousand conditions were screen using in-house and sparse matrix screens via sitting-drop methods at 4, 10, and 22 °C.
- KSR2(KD):MEK1 :ATP crystal structure (PDB code: 2Y4I). Model building and refinement was performed with Coot and Phenix (see e.g. , Emsley et al, Acta crystallographica. Section D, Biological crystallography, 2010, 66:486-501; and Adams et al, Acta crystallographica. Section D, Biological crystallography, 2010, 66:213-221). Crystals for the ATP and Compound 21 bound KSR2:MEK1 complexes share similar unit cell dimensions, space group symmetry, and X-ray diffraction properties.
- KSR2 binds MEK1 in a 1 :1 fashion within a quaternary arrangement that is nearly identical to the ATP-bound state of KSR2:MEK1 complexes (see e.g., Brennan et al, Nature, 2011, 472:366-369).
- KSR2 and MEK1 bind via a face-to- face arrangement mediated in large part through reciprocal helix aG and activation segment interactions, and KSR2 homo-dimerizes through the N-lobe along a crystallographic 2-fold symmetry axis producing a hetero-tetramer of KSR2:MEK1 dimers.
- Differences between the ATP- and Compound 21 bound states include variations in ligand occupancy and conformational changes at the level of secondary structural elements that are localized to KSR2.
- the MEK1 activation segment containing two phospho-regulatory sites (Ser218 and Ser222) necessary for MEK1 activation, is buried within the KSR2:MEK1 interaction interface.
- the KSR2:MEK1 Compound 21 structure revealed electron density for a portion of KSR2 that was not previously modeled, and therefore disordered in the ATP-bound complex, as shown in FIG. 6.
- This region encompassing residues Leu809 to Gln814, forms an extension of the activation segment C-terminal to the conserved DFG motif, and forms an anti-parallel beta-strand with residues Asp820 to Gln825 in KSR2.
- Asp820 through to Gln825 directly engages the activation segment of MEK1 burying the Ser218-Ser222 region, presumably shielding this segment of MEK from promiscuous phosphorylation.
- B-RAF was purified as previously described with slight modification (see e.g., Tsai et al, Proceedings of the National Academy of Sciences of the United States of America, 2008, 105:3041-3046).
- a variant of B-RAF was identified that could be expressed in high yield from E.Coli and which also retained near wild-type levels of kinase activity towards MEK1.
- indicated concentrations of B-RAF and 1 ⁇ KSR2-MEK1 or 1 ⁇ MEK1 proteins were pre- incubated with 10 ⁇ of indicated compounds for 15 minutes in buffer containing 25 mM Tris pH 7.5, 150 mMNaCl, 10 mM MgC12, and 2% DMSO.
- RAF can function as both an allosteric regulator of KSR and catalytic enzyme responsible for MEK phosphorylation (see e.g. , Farrar et al, Nature, 1996, 383: 178- 181; Brennan et al, Nature, 2011, 472:366-369; Huang et al, Proceedings of the National Academy of Sciences of the United States of America, 1993, 90:10947-
- bio-layer inferometry was utilized to monitor real-time association and dissociation of KSR2:MEK1 or free MEK1 to a sensor tethered with immobilized B-RAF.
- KSR2:B-RAF dimerization a mutation in B-RAF F667E was identified that eliminates binding to free MEK but not KSR2-MEK1 complexes, as shown in FIGs. 7C-7D.
- KSR2:MEK1 interacted in a 1 :1 fashion with the B-RAF F667E mutant with a KD of 1.99 +/- 0.09 ⁇ .
- this binding constant represents the dimerization constant for KSR2:B-RAF as it nearly matches previously published B-RAF:B-RAF dimerization values (see e.g., Rajakulendran et al, Nature, 2009, 461 :542-545).
- Ser218/Ser222 by RAF could be enhanced at least 10-fold in the presence of KSR, as shown in FIG. 8.
- KSR-stimulated MEK phosphorylation by RAF was significantly reduced by addition of Compound 21, as shown in FIGs. 9A-9C.
- FIGs. 9A-9C KSR-stimulated MEK phosphorylation by RAF
- Compound 21 was essentially inactive when KSR was absent or when the KSR2 A690F mutant was used for in vitro assays. Furthermore, Compound 21 lacked detectable inhibitory activity against purified forms of RAF, MEK, or ERK. Finally, Compound 21 was found to mimic the effects of RNAi based knockdown of KSRI in growth- factor stimulated cells, as shown in FIGs. 10A-10B.
- Model cell lines A375 (BRAF V600E positive) and HCT-116 (KRas G12D positive) were treated with the Compound 21 in combination with a MEK inhibitor, trametinib.
- a reduction in MAPK pathway readouts based on phospho-antibodies was observed when trametinib was combined with the Compound 21, as shown in FIG. 11.
- Model cell lines HCT-116, A549, and LOVO were plated at a density of 500 cells per well in a 96 well plate. Cell were then treated with increasing concentrations (0.1 ⁇ , 0.3 ⁇ , 1 ⁇ , 3 ⁇ , 10 ⁇ ) of Compound 21 ⁇ i.e., APS-2-79) for 72 hours. Cell viability was analyzed using the flourescent resazurin assay. Resazurin was added to each well to a final concentration of 0.02 mg/mL. After 3 h of incubation at 37 °C, cell viability was determined by measuring flouresence with an excitation 560 nM/590 nM emission filter set. FIGs. 15A-15C show the results of the in vitro cell assays using Compound 21.
- BLISS index was calculated by determining the difference between the expected combination value (the product of the viability ratio of drugl alone and drug2 alone) and the observed combination value (the viability ratio observed from combination treatment with drugl and drug2).
- the viability ratio represented the viability observed for treated (inhibitors) relative to controls (DMSO). The sum of these values across each 8 x 5 concentration matrix is presented in FIG. 12.
- the RAF- immobilized sensor heads were incubated with 5 different concentrations of purified KSR2:MEK1 complex (range: 625 nM to 10 ⁇ in two-fold dilutions). Association and dissociation was monitored over 660 and 840 seconds, respectively. Data sets were normalized and analysed using global fit binding models (Fortebio software). Kon and Koff were used to derive the KD values in FIGs. 7A-7G. OTHER EMBODIMENTS
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562148591P | 2015-04-16 | 2015-04-16 | |
PCT/US2016/027899 WO2016168704A1 (en) | 2015-04-16 | 2016-04-15 | Ksr antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3283466A1 true EP3283466A1 (en) | 2018-02-21 |
EP3283466A4 EP3283466A4 (en) | 2018-09-12 |
Family
ID=57126919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16780908.6A Pending EP3283466A4 (en) | 2015-04-16 | 2016-04-15 | Ksr antagonists |
Country Status (4)
Country | Link |
---|---|
US (1) | US10548897B2 (en) |
EP (1) | EP3283466A4 (en) |
CA (1) | CA2981886A1 (en) |
WO (1) | WO2016168704A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106699789A (en) * | 2017-02-07 | 2017-05-24 | 广东赛博科技有限公司 | Benzoquinazoline tyrosine kinase inhibitor containing cyanoaryl boronic acid as well as preparation method and application |
CN106749369A (en) * | 2017-02-07 | 2017-05-31 | 广东赛博科技有限公司 | The double ethoxy Benzoquinazole class Benzoquinazole class tyrosine kinase inhibitors of one class, Preparation Method And The Use |
CN106831837A (en) * | 2017-02-07 | 2017-06-13 | 广东赛博科技有限公司 | Aryl boric acid Benzoquinazole class tyrosine kinase inhibitor, Preparation Method And The Use of one class containing alkoxyphenyl radical |
CN106749371A (en) * | 2017-02-07 | 2017-05-31 | 广东赛博科技有限公司 | The aryl boric acid Benzoquinazole class tyrosine kinase inhibitor and purposes of one class nitrile group-containing phenyl |
CN106866715A (en) * | 2017-02-07 | 2017-06-20 | 广东赛博科技有限公司 | Benzoquinazole class tyrosine kinase inhibitor containing aryl boric acid structure, Preparation method and use |
CN106749368A (en) * | 2017-02-07 | 2017-05-31 | 广东赛博科技有限公司 | The Benzoquinazole class tyrosine kinase inhibitor and purposes of a kind of amino-contained aryl boric acid |
CN106831836A (en) * | 2017-02-07 | 2017-06-13 | 广东赛博科技有限公司 | The aryl boric acid Benzoquinazole class tyrosine kinase inhibitor and purposes of nitrobenzene-containing base |
CN106749370A (en) * | 2017-02-07 | 2017-05-31 | 广东赛博科技有限公司 | Benzoquinazole class tyrosine kinase inhibitor and purposes of one class containing aryl boric acid structure |
CN106831834A (en) * | 2017-02-07 | 2017-06-13 | 广东赛博科技有限公司 | A kind of Benzoquinazole class tyrosine kinase inhibitor and purposes containing nitroaryl boric acid |
CN106831835A (en) * | 2017-02-07 | 2017-06-13 | 广东赛博科技有限公司 | Tyrosine kinase inhibitor and purposes of one class containing the double ethyoxyl benzo quinazoline ditosylate salt structures of halo |
CN106749367A (en) * | 2017-02-07 | 2017-05-31 | 广东赛博科技有限公司 | The aryl boric acid Benzoquinazole class tyrosine kinase inhibitor of amino-contained phenyl, Preparation Method And The Use |
CN106831838A (en) * | 2017-02-07 | 2017-06-13 | 广东赛博科技有限公司 | Aryl boric acid and Benzoquinazole class tyrosine kinase inhibitor containing alkoxy substitution |
CN110423218A (en) * | 2019-08-09 | 2019-11-08 | 新乡双鹭药业有限公司 | A kind of rich preparation method for impurity in Buddhist nun's synthesis of malic acid card |
EP4087868A4 (en) * | 2020-01-08 | 2024-03-20 | Icahn School Med Mount Sinai | Small molecule modulators ksr-bound mek |
CA3200814A1 (en) | 2020-12-02 | 2022-06-09 | Alfredo C. Castro | Tead inhibitors and uses thereof |
WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2022159986A1 (en) | 2021-01-25 | 2022-07-28 | Ikena Oncology, Inc. | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer |
WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (en) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
IL148576A0 (en) * | 1999-09-21 | 2002-09-12 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
SK3832002A3 (en) | 1999-09-21 | 2002-11-06 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2003033472A1 (en) | 2001-10-17 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors |
CN1688549A (en) * | 2002-08-23 | 2005-10-26 | 麒麟麦酒株式会社 | Compound having TGF-beta inhibitory activity and medicinal composition containing the same |
CN1984660B (en) | 2003-07-03 | 2010-12-15 | 美瑞德生物工程公司 | 4-arylamino-quinazolines as activators of aspartic acid specificity cysteine protease and inducers of apoptosis |
WO2014017659A1 (en) | 2012-07-27 | 2014-01-30 | 独立行政法人理化学研究所 | Agent for treating or controlling recurrence of acute myelogenous leukemia |
TW201427958A (en) | 2012-09-14 | 2014-07-16 | Univ Nat Yang Ming | Aryl amine substituted pyrimidine and quinazoline and their use as anticancer drugs |
US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
CN105017256A (en) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | Polyfluorinated compound Bruton tyrosine kinase inhibitor |
-
2016
- 2016-04-15 EP EP16780908.6A patent/EP3283466A4/en active Pending
- 2016-04-15 CA CA2981886A patent/CA2981886A1/en not_active Abandoned
- 2016-04-15 WO PCT/US2016/027899 patent/WO2016168704A1/en unknown
- 2016-04-15 US US15/566,565 patent/US10548897B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2981886A1 (en) | 2016-10-20 |
US10548897B2 (en) | 2020-02-04 |
US20180256577A1 (en) | 2018-09-13 |
WO2016168704A1 (en) | 2016-10-20 |
EP3283466A4 (en) | 2018-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10548897B2 (en) | KSR antagonists | |
CA2969090C (en) | Triazolopyrimidine compounds and uses thereof | |
US11440914B2 (en) | Tricyclic amine compounds as CDK2 inhibitors | |
AU2015244044B2 (en) | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitor | |
KR102449712B1 (en) | Aminothiazole compounds and uses thereof | |
JP2021020957A (en) | Methods to induce targeted protein degradation through bifunctional molecules | |
JP2023103242A (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
JP2020514254A (en) | Compositions and methods for treating cancer | |
ES2465094T3 (en) | AKT inhibitors | |
EP3867251A1 (en) | Kras g12c inhibitors | |
US20190202840A1 (en) | Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one | |
US20160031890A1 (en) | Novel methods, compounds, and compositions for inhibition of ros | |
KR20210151820A (en) | Compositions and methods for treating cancer | |
KR20190128673A (en) | Pyrimidopyrimidinone Useful as Wee-1 Kinase Inhibitor | |
EP4087868A1 (en) | Small molecule modulators ksr-bound mek | |
WO2020033782A1 (en) | Activators of the retinoic acid inducible gene "rig-1" pathway and methods of use thereof | |
JP2022539208A (en) | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | |
AU2020374269A1 (en) | Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same | |
EP3471729B1 (en) | Isoxazolmethylthio-, thienylmethylthio- and thiazomethylthio-derivatives for use in the treatment of cancer; viral infections; thrombotic events or platelet aggregation | |
CA3107750A1 (en) | Cdk inhibitors and uses thereof | |
KR20220042136A (en) | heterocyclic compound | |
JP2023513016A (en) | Aminopyrimidinyl aminobenzonitrile derivatives as NEK2 inhibitors | |
WO2021189036A1 (en) | Taf1 inhibitors | |
WO2023172880A2 (en) | Pcna inhibitors and uses thereof | |
EA028800B1 (en) | Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20171115 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DHAWAN, NEIL Inventor name: DAR, ARVIN Inventor name: SCOPTON, ALEX P. |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20180816 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/519 20060101ALI20180809BHEP Ipc: C07D 239/94 20060101AFI20180809BHEP Ipc: C07D 239/74 20060101ALI20180809BHEP Ipc: C07D 239/93 20060101ALI20180809BHEP Ipc: C07D 239/88 20060101ALI20180809BHEP Ipc: A61P 35/00 20060101ALI20180809BHEP Ipc: C07D 239/86 20060101ALI20180809BHEP Ipc: A61K 31/517 20060101ALI20180809BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230714 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |